Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women

HIV Medicine

Volumn 9, Issue 1, 2008, Pages 6-13

  Grosch Woerner, Ilse ^a   Puch, K ^a   Maier, R F ^a   Niehues, T ^b   Notheis, G ^c   Patel, D ^d   Casteleyn, S ^a   Feiterna Sperling, C ^a   Groeger, S ^e   Zaknun, D ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e University College London ^*  (Germany)

^f UNIVERSITY OF VIENNA   (Austria)

Author keywords

Congenital abnormalities; HAART; HIV; Pregnancy; Prematurity

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; AUSTRIA; BIRTH WEIGHT; CESAREAN SECTION; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONGENITAL DISORDER; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GERMANY; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFANT MORTALITY; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PREMATURITY; PRENATAL PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRIA; BIRTH WEIGHT; CONGENITAL ABNORMALITIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME;

EID: 38349019417     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00520.x     Document Type: Article

References (38)

1. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-1180.
2. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-987.
3. European Collaborative Study. Are girls more at risk of intrauterine-acquired HIV infection than boys? AIDS 2004; 18: 344-347.
4. Dorenbaum A, Cunningham CK, Gelber RD et al. Two-dose intrapartum/ newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: A randomized trial. JAMA 2002; 288: 189-198.
5. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-387.
6. Grosch-Worner I, Schafer A, Obladen M et al. An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 2000; 14: 2903-2911.
7. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: Evolving in the East and established in the West. AIDS 2006; 20: 1419-1427.
8. Lorenzi P, Spicher VM, Laubereau B et al. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998; 12: F241-F247.
9. ECS and Swiss Cohort and European Collaborative Study and the Swiss HIV Pregnancy Cohort. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-2920.
10. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-2339.
11. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis. AIDS 2007; 21: 607-615.
12. Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863-1870.
13. Tuomala RE, Watts DH, Li D et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38: 449-473.
14. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 1195-1201.
15. European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 2005; 40: 116-118.
16. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry Interim Report, 2006.
17. Queisser-Luft A, Stolz G, Wiesel A, Schlaefer K, Spranger J. Malformations in newborn: Results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990-1998). Arch Gynecol Obstet 2002; 266: 163-167.
18. Brockmeyer N. German-Austrian Guidelines for HIV-therapy during pregnancy - status: May/June 1998 -common statement of the Deutsche AIDS-Gesellschaft (DAIG) and the Osterreichische AIDS-Gesellschaft (OAG). Eur J Med Res 1999; 4: 35-42.
19. Buchholz B, Marcus U, Beichert M et al. German - Austrian recommendations for HIV-therapy in pregnancy - update 2001. http://www.rki.de
20. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17: 407-429.
21. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007; 119: E900-e906.
22. Patel D, Thorne C, Newell M-L. Response to Kourtis et al., 'Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis'. AIDS 2007; 21: 1656-1657.
23. Newell ML, Parazzini F, Mandelbrot L et al. A randomised trial of mode of delivery in women infected with the human immunodeficiency virus. Br J Obstet Gynaecol 1998; 105: 281-285.
24. Dunn DT, Newell ML, Mayaux MJ et al. Mode of delivery and vertical transmission of HIV-1: A review of prospective studies. Perinatal AIDS Collaborative Transmission Studies. J Acquir Immune Defic Syndr 1994; 7: 1064-1066.
25. Shankaran S, Das A, Bauer CR et al. Association between patterns of maternal substance use and infant birth weight, length, and head circumference. Pediatrics 2004; 114: E226-e234.
26. Neu N, Leighty R, Adeniyi-Jones S et al. Immune parameters and morbidity in hard drug and human immunodeficiency virus-exposed but uninfected infants. Pediatrics 2004; 113: 1260-1266.
27. Boer K, Smit BJ, van Huis AM, Hogerzeil HV. Substance use in pregnancy: do we care? Acta Paediatr 1994; 404 (Suppl.): 65-71.
28. The European Collaborative Study. Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996; 10: 1675-1681.
29. O'Shea S, Newell ML, Dunn DT et al. Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J Med Virol 1998; 54: 113-117.
30. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-1026.
31. Lu GC, Goldenberg RL. Current concepts on the pathogenesis and markers of preterm births. Clin Perinatol 2000; 27: 263-283.
32. European Collaborative Study. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr 2005; 40: 364-370.
33. Fiore S, Newell ML, Trabattoni D et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70: 143-150.
34. European Collaborative Study. Management of vertically HIV-infected children in Europe. Acta Paediatr 2003; 92: 246-250.
35. Friese K, Kirschner W. Das BabyCare-Projekt. Konzept, erste Ergebnisse und Erfolgskriterien. Gynäkologe 2003; 36: 403-412.
36. Morrison JC. Preterm birth: A puzzle worth solving. Obstet Gynecol 1990; 76: 5S-12S.
37. European Collaborative Study. Increasing likelihood of further live births in HIV-infected women in recent years. Br J Obstetr Gynaecol 2005; 112: 881-888.
38. Gilling-Smith C, Nicopoullos JD, Semprini AE, Frodsham LC. HIV and reproductive care - a review of current practice. Br J Obstetr Gynaecol 2006; 113: 869-878.